近年来放射免疫治疗(RIT)有了很大的发展,两个放射免疫结合物,90Y-ibritumomab tiuxetan和131 I-tositumomab已获得美国FDA批准用于治疗B细胞性非霍奇金淋巴瘤(NHL),尚有一些放射免疫结合物正在进行临床试验。放射免疫结合物治疗惰性NHL,有效率约80％,完全缓解率25％-30%;主要不良反应为可逆转的骨髓抑制。现综述RIT在B细胞NHL的作用机制及研究进展。 In recent years there has been a great development in radioimmunotherapy (RIT). Two radioimmunoconjugates, 90Y-ibritumomab tiuxetan and 131 I-tositumomab, have been approved by the U.S. FDA for the treatment of B-cell non-Hodgkin’s lymphoma (NHL ), There are still some radioimmunoconjugates in clinical trials. Radioimmunoconjugate treatment of inert NHL, the effective rate of about 80%, the complete remission rate of 25% -30%; the main adverse reaction is reversible myelosuppression. The mechanism of RIT in B cell NHL and its research progress are summarized.